Second-Line Chemotherapy for Intrahepatic Cholangiocarcinomas: What Is the Real Gain?

Background: The presence of actionable alterations in advanced biliary tract cancer patients opened new therapeutic possibilities for second-line treatments. However, for around 60% of the patients, chemotherapy remains the only therapeutic option. The aim of our study was to evaluate outcomes and p...

Descripción completa

Detalles Bibliográficos
Autores principales: Garajová, Ingrid, Gelsomino, Fabio, Salati, Massimiliano, Mingozzi, Anna, Peroni, Marianna, De Lorenzo, Stefania, Granito, Alessandro, Tovoli, Francesco, Leonardi, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672315/
https://www.ncbi.nlm.nih.gov/pubmed/38004310
http://dx.doi.org/10.3390/life13112170

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10672315/
https://www.ncbi.nlm.nih.gov/pubmed/38004310
http://dx.doi.org/10.3390/life13112170

Ejemplares similares